Xinyao Xu

Xinyao Xu

Auto-generated profile, based on publicly available information

Xinyao Xu

Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, No. 5 Beixiange, Xicheng District, Beijing 100053, China; Beijing University of Chinese Medicine, No. 11 North Third Ring Road East, Chaoyang District, Beijing 100029, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2016 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
QGQiujun Guo
Qiujun Guo
ZJZhichao Jin
Zhichao Jin
YYYuan Yuan
Yuan Yuan
RLRui Liu
Rui Liu
TXTao Xu
Tao Xu
BHBaojin Hua
Baojin Hua
The majority of basic and clinical studies have shown a protumor function of tumor-associated macrophages (TAMs), which represent a large proportion of matrix cells. TAMs promote tumorigenesis, and their number is related to the malignancy degree and poor prognosis of many kinds of tumors. Macrophage plasticity makes it possible to change the tumor microenvironment and remodel antitumor immunity during cancer immunotherapy. Increasing numbers of studies have revealed the effects of TAMs on the tumor microenvironment, for example, via promotion of tumor growth and tumorigenesis and through an increase in the number of cancer stem cells or via facilitation of angiogenesis, lymphangiogenesis, and metastasis. Investigators also proposed tumor-immunological treatments targeting TAMs by inhibiting TAM recruitment and differentiation, by regulating TAM polarization, and by blocking factors and pathways associated with the protumor function of TAMs. This comprehensive review presents recent research on TAMs in relation to prediction of poor outcomes, remodeling of the tumor immune microenvironment, and immunological targeted therapies.

1 January 2016 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
TXTao Xu
Tao Xu
ZJZhichao Jin
Zhichao Jin
YYYuan Yuan
Yuan Yuan
HWHuamin Wei
Huamin Wei
XXXinyao Xu
Xinyao Xu
BHBaojin Hua
Baojin Hua
Objective. To evaluate ginsenoside Rg3 combined with chemotherapy for non‐small‐cell lung cancer (NSCLC) treatment, in a meta‐analysis. Materials and Methods. We searched PubMed, EMBASE, the Cochrane Library, the China National Knowledge Infrastructure, and the VIP and Wanfang databases for eligible studies. We manually searched for printed journals and relevant textbooks. Statistical analyses were performed with Revman 5.3 and STATA 14.0 software packages. Results. Twenty studies were included. Ginsenoside Rg3 combined with chemotherapy could enhance response, improve disease control, prolong overall survival, improve patient quality of life, reduce leucocyte count decrease due to chemotherapy, reduce vascular endothelial growth factor expression in peripheral blood, and increase CD4/CD8 T cell ratio. Conclusion. Ginsenoside Rg3 combined with chemotherapy may enhance short‐term efficacy and overall survival, alleviate treatment‐induced side effects, reduce vascular endothelial growth factor expression, increase CD4/CD8 T cell ratio, and serve as a potential therapeutic regimen for NSCLC. However, considering the limitations, the conclusion should be interpreted carefully, and these results need to be confirmed by more high‐quality trials.

1 January 2018 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
XZXing Zhang
Xing Zhang
YYYuan Yuan
Yuan Yuan
YXYupeng Xi
Yupeng Xi
XXXinyao Xu
Xinyao Xu
QGQiujun Guo
Qiujun Guo
BHBaojin Hua
Baojin Hua
Gastric cancer has a high morbidity and mortality. Chemotherapy regimens are routine advanced stage gastric cancer (AGC) treatment protocols, but most of these drugs have side‐effects such as myelosuppression and gastrointestinal disorders. Cinobufacini, an extractive from TCM, could suppress cell proliferation and inhibit gastric cancer. In this study, we comprehensively reviewed the literature on the efficacy comparison between Cinobufacini injection combined with chemotherapy and chemotherapy solely used in AGC treatment. We extracted data for from six electronic databases to evaluate the efficacy of Cinobufacini injection on AGC patients. Twelve studies with a total of 853 patients were finally included in our study. The results indicated that Cinobufacini injection could increase response rate and disease control rate of chemotherapy on AGC, improve the life quality of AGC patients, increase leukocytes, improve anemia, improve hand‐foot syndrome induced by chemotherapy, and relieve cancer pain. This study has its own limitations that prevented us from drawing a definite conclusion and more well‐designed clinical trials of TCM are needed.

29 July 2018 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
QGQiujun Guo
Qiujun Guo
ZJZhichao Jin
Zhichao Jin
YYYuan Yuan
Yuan Yuan
RLRui Liu
Rui Liu
TXTao Xu
Tao Xu
BHBaojin Hua
Baojin Hua
[This corrects the article DOI: 10.1155/2016/9720912.].